Stobadine-inhibitor of cyclophosphamide-induced micronuclei in mice.
The potential antimutagenic effect of stobadine dipalmitate (STB) on the frequency of micronuclei in reticulocytes of peripheral blood in female ICR mice was studied. The cyclophosphamide model was used to verify this effect. Stobadine dipalmitate was administered orally in three concentrations: STB I, 7.07; STB II, 23.6; STB III, 70.07 mg/kg body wt 2 h prior to or 4 h after (STB II only) cyclophosphamide administration (intraperitoneally, twice 80 mg/kg body wt with a 24 h interval). The method designed by Hayashi et al. [(1990) Mutat. Res., 245, 245-249] was used to prepare and to stain the slides. The results of the experiment show that pretreatment with stobadine 2 h prior to cyclophosphamide administration significantly decreased its mutagenic effect, as manifested by the reduced frequency of micronucleated reticulocytes. This protective effect of stobadine was concentration-dependent with the highest concentration of stobadine inducing the most pronounced decrease of micronuclei. Analysis and identification of the exact mechanism of the protective effects of stobadine is the aim of our further studies.
Chorvatovicová
D
D
Institute of Experimental Pharmacology, Slovak Academy of Sciences, Bratislava.
Bauer
V
V
D000818:Animals; D016587:Antimutagenic Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology*; D002243:Carbolines / Q000008:administration & dosage / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors* / Q000633:toxicity; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects*; D015162:Micronucleus Tests; D012156:Reticulocytes / Q000187:drug effects / Q000648:ultrastructure; D013997:Time Factors
D016587:Antimutagenic Agents; D000975:Antioxidants; D002243:Carbolines; D003520:Cyclophosphamide; C100106:dicarbine